Welcome to the CCO Site

Thank you for your interest in CCO content. As a guest, please complete the following information fields. These data help ensure our continued delivery of impactful education. 

Become a member (or login)? Member benefits include accreditation certificates, downloadable slides, and decision support tools.

Submit

CCO Independent Conference Coverage of ECCO 2022: Clinical Impact of New Data on Crohn’s Disease and Ulcerative Colitis
  • CME

Credits Available
Physicians: maximum of 0.75 AMA PRA Category 1 Credits
Released: May 19, 2022 Expiration: May 18, 2023
Start Activity
Provided by Clinical Care Options, LLC

Contact Clinical Care Options

For customer support please email: customersupport@cealliance.com

Mailing Address
Clinical Care Options, LLC
12001 Sunrise Valley Drive
Suite 300
Reston, VA 20191

Supported by an educational grant from
Bristol-Myers Squibb
Uma Mahadevan, MD
Bruce E. Sands, MD, MS

Learning Objectives

Upon completion of this activity, participants should be able to:
  • Consider key findings from recent studies of current IBD therapies and how they may modify treatment decisions
  • Summarize efficacy and safety results of novel investigational IBD therapies that have the potential to provide additional treatment options for patients who fail standard therapies

Information on this Educational Activity

Clinical Care Options, LLC (CCO) requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose all financial conflicts of interest (COI) they may have with ineligible companies. All relevant COI are thoroughly vetted and mitigated according to CCO policy. CCO is committed to providing its learners with high-quality CME/CE activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of an ineligible company.

The faculty reported the following relevant financial relationships or relationships to products or devices they have with ineligible companies related to the content of this educational activity:

Faculty

Uma Mahadevan, MD

Professor of Medicine, Division of Gastroenterology
Director, Center for Colitis and Crohn’s Disease
University of California San Francisco Medical School
San Francisco, California

Uma Mahadevan, MD, has disclosed that she has received consulting fees from AbbVie, Arena, Bristol-Myers Squibb, Boehringer Ingelheim, Calibr, Gilead, Janssen, Pfizer, Prometheus Biosciences, Protagonist, Surrozen, and Takeda.
Bruce E. Sands, MD, MS

Dr. Burrill B. Crohn Professor of Medicine
Chief of the Dr. Henry D. Janowitz Division of Gastroenterology

Mount Sinai Hospital
Chief, Division of Gastroenterology
Mount Sinai Health System
Director, Digestive Disease Institute
Icahn School of Medicine at Mount Sinai
New York, New York

Bruce E. Sands, MD, MS, has disclosed that he has received funds for research support from Janssen and Theravance Biopharma R&D; has received consulting fees from Abivax, AbbVie, Alimentiv, Amgen, Arena, Artugen, AstraZeneca, Bacainn, Boehringer Ingelheim, Boston Pharmaceuticals, Bristol-Myers Squibb, Calibr, Celltrion, ClostraBio, Enthera, Evommune, Ferring, Galapagos, Gilead, GlaxoSmithKline, GossamerBio, Immunic, Index, Innovation, Ironwood, Janssen, Kaleido, Kallyope, Lilly, MiroBio, MRM Health, Morphic Therapeutic, Pfizer, Progenity, Prometheus Biosciences, Protagonist Therapeutics, Q32 Bio, Sun Pharma, Surrozen, Takeda, Target RWE, Teva Branded Pharmaceutical Products R&D, Thelium, Theravance Biopharma R&D, TLL Pharma, USWM Enterprises, Ventyx Biosciences, Viela Bio; and has ownership interest in Ventyx.

Staff

Erin Puritz, PharmD
Erin Puritz, PharmD, BCPS, BCCCP, has no relevant conflicts of interest to report.
Ruth Cohen
Ruth Cohen Cooper, CHCP, has no relevant conflicts of interest to report.
Kiran D. Mir-Hudgeons, PhD

Manager, Editorial Operations

Kiran D. Mir-Hudgeons, PhD, has no relevant conflicts of interest to report.
Craig Borders
Vice President, Managing Scientific Director
Craig R. Borders has no relevant conflicts of interest to report.
Anna Poppa

Editorial Contributor

Anna Poppa, MS, has no relevant conflicts of interest to report.

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications.

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Disclaimer

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

Target Audience

This program is intended for physicians and other HCPs who care for patients with IBD.

Goal

The goal of this activity is to improve learners’ competence in translating the most clinically significant data from ECCO 2022 into evidence-based management strategies for individuals with inflammatory bowel disease (IBD).

Accreditation

Joint Accreditation Statement

In support of improving patient care, Clinical Care Options, LLC (CCO) is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Physician Continuing Medical Education

Credit Designation

CCO designates this enduring material for a maximum of 0.75 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Program Medium

This program has been made available online.

Instructions for Credit

Participation in this self-study activity should be completed in approximately 0.75 hours. To successfully complete this activity and receive credit, participants must follow these steps during the period from May 19, 2022, through May 18, 2023:

1. Register online at http://www.clinicaloptions.com.
2. Read the target audience, learning objectives, and faculty disclosures.
3. Study the educational activity online or printed out.
4. Submit answers to the posttest questions and evaluation questions online.

You must receive a test score of at least 65% and respond to all evaluation questions to receive a certificate. After submitting the evaluation, you may access your online certificate by selecting the certificate link on the posttest confirmation page. Records of all CME/CE activities completed can be found on the "CME/CE Manager" page. There are no costs/fees for this activity.

CCO Independent Conference Coverage of ECCO 2022: Clinical Impact of New Data on Crohn’s Disease and Ulcerative Colitis
  • CME

Loading...
February 16-19, 2022; Virtual
In this webcast, expert faculty translate and discuss the most clinically significant data from ECCO 2022 into evidence-based management strategies for patients with Crohn disease and ulcerative colitis.
Uma Mahadevan, MD
Bruce E. Sands, MD, MS
Physicians: maximum of 0.75 AMA PRA Category 1 Credits
Released: May 19, 2022 Expiration: May 18, 2023

Related Content

Experts review new treatment strategies in IBD and how to address health inequities in patients, from Clinical Care Options (CCO)

Anita Afzali, MD, MPH, MHCM, FACG, AGAF
Program Director
David Hudesman, MD, FACG, AGAF Millie D. Long, MD, MPH, FACG, AGAF
Physicians: maximum of 1.5 AMA PRA Category 1 Credits Registered Nurses: 1.5 Nursing contact hours Physician Assistants: maximum of 1.5 hours of AAPA Category 1 CME credits Released: June 24, 2022 Expired: June 23, 2023

Drs. Anita Afzali, Millie Long, David Hudesman on latest IBD treatments, therapeutic challenges, individualized care, health inequity from Clinical Care Options (CCO)

Anita Afzali, MD, MPH, MHCM, FACG, AGAF
Program Director
David Hudesman, MD, FACG, AGAF Millie D. Long, MD, MPH, FACG, AGAF
Released: May 20, 2022

Clinical Care Options (CCO) presents expert commentary on new data in Crohn disease and ulcerative colitis from ECCO 2022

Bruce E. Sands, MD, MS Released: May 13, 2022

Expert slides from Clinical Care Options (CCO) on new data from ECCO 2022 17th Congress Meeting in patients with Crohn disease and ulcerative colitis

Uma Mahadevan, MD Bruce E. Sands, MD, MS Released: May 6, 2022
Provided by Clinical Care Options, LLC

Contact Clinical Care Options

For customer support please email: customersupport@cealliance.com

Mailing Address
Clinical Care Options, LLC
12001 Sunrise Valley Drive
Suite 300
Reston, VA 20191

Supported by an educational grant from
Bristol-Myers Squibb

Leaving the CCO site

You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.

Continue

Cookie Settings